AZD7442 reduces COVID-19 risks by 83 percent in Phase III trial
A separate treatment trial showed 88 percent reduced risk of severe COVID-19 or death when treated within three days of symptom onset.
List view / Grid view
A separate treatment trial showed 88 percent reduced risk of severe COVID-19 or death when treated within three days of symptom onset.
The Europe Medicines Agency (EMA)'s human medicine committee advise (CHMP) that Lagevrio can be used for COVID-19 patients who do not require oxygen and are at increased risk.
The US Food and Drug Administration (FDA) approves vosoritide injection to improve growth in children at least five years of age with achondroplasia and open epiphyses.
Milvexian showed a 12 percent rate of postoperative venous thromboembolism compared to the benchmark rate of 30 percent in a Phase II study.
At week 48 of the Phase II trial, 65 percent of patients with Crohn's disease receiving Tremfya® achieved clinical remission.
The European Commission (EC) has granted marketing authorisation for Vumerity® to treat adults with relapsing-remitting multiple sclerosis.
The US Food and Drug Administration (FDA) approves Besremi (ropeginterferon alfa-2b-njft) injection to treat adults with polycythemia vera.
A clinical trial found that all-trans retinoic acid and arsenic trioxide is an effective treatment for acute promyelocytic leukaemia.
The European Medicines Agency’s human medicines committee (CHMP) has recommended authorising Ronapreve™ and Regkirona for COVID-19.
Cosentyx® resulted in a 72 percent reduced flare risk for enthesitis-related arthritis and juvenile psoriatic arthritis in a Phase III study.
COMP360 25mg versus 1mg comparator dose demonstrated a -6.6 point difference on the Montgomery-Åsberg Depression Rating Scale by week 3.
Amgen announces positive results from the first and only randomised, double-blind, head-to-head study comparing Aimovig® to topiramate.
In the analysis, 34 percent of rheumatoid arthritis patients receiving Rinvoq® achieved Clinical Disease Activity Index (CDAI) remission.
Novo Nordisk's Wegovy™ reduced body weight by 15.2 percent versus 2.6 percent with placebo in Phase IIIb study.
Paxlovid™, Pfizer's investigational oral antiviral candidate, displayed an 89 percent reduction in COVID-19 risks in Phase II/III study.